VIIV HEALTHCARE PTY LTD

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

First Posted Date
2012-05-14
Last Posted Date
2012-09-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
14
Registration Number
NCT01597895
Locations
πŸ‡§πŸ‡ͺ

Pfizer Investigational Site, Bruxelles, Belgium

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

First Posted Date
2012-04-02
Last Posted Date
2018-07-02
Lead Sponsor
ViiV Healthcare
Target Recruit Count
30
Registration Number
NCT01568892
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Annandale, Virginia, United States

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

First Posted Date
2012-03-26
Last Posted Date
2017-03-28
Lead Sponsor
ViiV Healthcare
Target Recruit Count
32
Registration Number
NCT01563328
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Austin, Texas, United States

Dolutegravir Expanded Access Study

First Posted Date
2012-02-22
Last Posted Date
2020-09-30
Lead Sponsor
ViiV Healthcare
Target Recruit Count
200
Registration Number
NCT01536873
Locations
πŸ‡΅πŸ‡±

GSK Investigational Site, Szczecin, Poland

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

First Posted Date
2011-12-26
Last Posted Date
2012-05-21
Lead Sponsor
ViiV Healthcare
Target Recruit Count
16
Registration Number
NCT01498861
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Miami, Florida, United States

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-12-26
Last Posted Date
2015-02-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
13
Registration Number
NCT01499199
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Providence, Rhode Island, United States

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

First Posted Date
2011-11-08
Last Posted Date
2012-10-15
Lead Sponsor
ViiV Healthcare
Target Recruit Count
28
Registration Number
NCT01467531
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Buffalo, New York, United States

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

First Posted Date
2011-11-08
Last Posted Date
2012-04-09
Lead Sponsor
ViiV Healthcare
Target Recruit Count
11
Registration Number
NCT01467518
Locations
πŸ‡¨πŸ‡¦

GSK Investigational Site, Toronto, Ontario, Canada

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Completed
Conditions
First Posted Date
2011-10-24
Last Posted Date
2019-09-11
Lead Sponsor
ViiV Healthcare
Target Recruit Count
19
Registration Number
NCT01458132
Β© Copyright 2024. All Rights Reserved by MedPath